Home | Contact Us | Search | Site Map
Crucell
H5N1 Avian Antibodies




Avian Influenza H5N1 Virus Antibodies
Description
Crucell has discovered the first human monoclonal antibodies for the prevention and treatment of avian flu. The antibodies provide immediate protection and neutralize the broadest range of H5N1 strains in pre-clinical models.
Development Rationale

There is a growing fear within the medical community concerning the potential re-occurance of a pandemic influenza outbreak, similar to the 1918 “Spanish flu” pandemic. A pandemic can start when a new influenza virus subtype emerges that meets three conditions: it infects humans causing serious illness; it spreads easily; and there is sustained human-to-human transmission of the virus. The H5N1 virus meets the first two conditions, and the risk that the virus acquires the third ability will persist as long as opportunities for human infections occur.

 

Vaccines effective against a pandemic virus are not yet available. Although vaccines against H5N1 virus are under development, no vaccine is ready for commercial production and no vaccines are expected to be available until several months after the start of a pandemic. Clinical data on the use of anti-viral drugs to treat H5N1 virus infections is limited at this time.

 

Crucell has discovered a total of twenty-one human monoclonal antibodies that have been found to neutralize the avian influenza H5N1 virus. The set of monoclonal antibodies, which was produced by Crucell researchers using phage display and Crucell PER.C6® technology, showed the potential to neutralize the broadest range of H5N1 viruses including A/Vietnam/11994/04, A/Hong Kong/213/03 and A/Hong Kong/156/97. The antibodies apparently recognize a part of the viral membrane protein that is present among all H5N1 viruses tested. The most potent neutralizing antibody was tested in pre-clinical models for the ability to protect against infection with the highly pathogenic A/Hong Kong/97 H5N1 virus and was also tested for its ability to stop the development of the disease caused by this virus. When the monoclonal antibody was given in a pre-clinical model, one day prior to infection with the H5N1 virus, it resulted in full protection against infection. Treatment with the antibody up to three days after infection resulted in 100% survival and cure of the disease. This antibody may therefore provide a powerful tool in pandemic preparedness.
Development Status
Crucell has delivered proof of concept that the H5N1 virus antibodies are a serious alternative to vaccination or antiviral treatment.
About Avian and Pandemic Influenza

Avian influenza is an infection caused by avian, or bird, influenza viruses that occur naturally among wild birds. It is usually very contagious among birds and can make some domestic poultry (chickens, ducks or turkeys) very sick and potentially kill them. Although uncommon, infections with these viruses can occur in humans. Of the hundreds of strains of avian influenza A viruses, only four are known to have caused human infections: H5N1, H7N3, H7N7, and H9N2. Since 1997, more than 230 confirmed cases of human infection with avian influenza strains, principally the influenza A virus H5N1, have been reported resulting in death in more than 50% of those infected. Most cases have occured from close contact with infected poultry or with secretions or excretions from infected birds. The spread of avian influenza viruses from person to person has been reported very rarely.

 

Pandemic flu is a virulent human flu that causes a global outbreak, or pandemic, of serious illness. During the 20th century there were three influenza pandemics, with the 1918 “Spanish” flu causing up to 50 million deaths worldwide. Genetic studies have confirmed that the H5N1 virus mutates rapidly. Should it adapt to allow easy human-to-human transmission, a pandemic could ensue. Because there is little natural immunity, the disease can spread easily from person to person. At this time, it is uncertain whether the currently circulating H5N1 virus will lead to a pandemic in humans.
MoveNext - Latus © Crucell 2006 | Disclaimer